LinkedIn Profile

Access Synergy Pharmaceuticals historical Linkedin company profile data on number of followers, employee headcount and more

Rows

Open dataset
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Headcount change in past 24 months Company Name Sector Industry
nasdaq:sgyp 2693782 Mar 1st, 2022 12:00AM Synergy Pharmaceuticals Inc. 4.1K 38.00 Open Biotechnology Mar 1st, 2022 10:02AM Mar 1st, 2022 10:02AM At Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), we’re igniting change in gastrointestinal (GI) medicine to develop new treatments with the potential to improve the lives of patients. Our values guide every aspect of our business—our relationships with customers, our approach to science and innovation, and our vision of a healthier future for patients. For more than 20 years, our scientists have been relentlessly committed to developing differentiated therapies for the GI market. Since the late 1990s, we have been focused on pioneering the research and development of uroguanylin analogs, a naturally occurring human GI peptide, through our clinical work. Our goal is to develop innovative treatments that improve efficacy, safety and tolerability and deliver a better experience for patients living with chronic idiopathic constipation (CIC), irritable bowel syndrome with constipation (IBS-C), opioid-induced constipation (OIC), and ulcerative colitis (UC). We are committed to scientifically driven innovation, providing novel treatment options for patients and healthcare providers, rewarding opportunities for our employees, and creating exceptional value for our customers. You can find us based in New York City, with research, technical operations and commercial offices in suburban Philadelphia. Learn more about our company here: http://www.synergypharma.com/about-us You can also follow us on Twitter: @SynergyPharma Open Innovation, Biotechnology, Gastrointestinal (GI) research and development, Gastrointestinal therapies Open 420 Lexington Avenue, Suite 2012 New York City New York US 10170 Synergy Pharmaceuticals Health Care Pharmaceuticals & Biotechnology
nasdaq:sgyp 2693782 Feb 28th, 2022 12:00AM Synergy Pharmaceuticals Inc. 4.1K 38.00 Open Biotechnology Feb 28th, 2022 09:57AM Feb 28th, 2022 09:57AM At Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), we’re igniting change in gastrointestinal (GI) medicine to develop new treatments with the potential to improve the lives of patients. Our values guide every aspect of our business—our relationships with customers, our approach to science and innovation, and our vision of a healthier future for patients. For more than 20 years, our scientists have been relentlessly committed to developing differentiated therapies for the GI market. Since the late 1990s, we have been focused on pioneering the research and development of uroguanylin analogs, a naturally occurring human GI peptide, through our clinical work. Our goal is to develop innovative treatments that improve efficacy, safety and tolerability and deliver a better experience for patients living with chronic idiopathic constipation (CIC), irritable bowel syndrome with constipation (IBS-C), opioid-induced constipation (OIC), and ulcerative colitis (UC). We are committed to scientifically driven innovation, providing novel treatment options for patients and healthcare providers, rewarding opportunities for our employees, and creating exceptional value for our customers. You can find us based in New York City, with research, technical operations and commercial offices in suburban Philadelphia. Learn more about our company here: http://www.synergypharma.com/about-us You can also follow us on Twitter: @SynergyPharma Open Innovation, Biotechnology, Gastrointestinal (GI) research and development, Gastrointestinal therapies Open 420 Lexington Avenue, Suite 2012 New York City New York US 10170 Synergy Pharmaceuticals Health Care Pharmaceuticals & Biotechnology
nasdaq:sgyp 2693782 Feb 27th, 2022 12:00AM Synergy Pharmaceuticals Inc. 4.1K 38.00 Open Biotechnology Feb 27th, 2022 04:04PM Feb 27th, 2022 04:04PM At Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), we’re igniting change in gastrointestinal (GI) medicine to develop new treatments with the potential to improve the lives of patients. Our values guide every aspect of our business—our relationships with customers, our approach to science and innovation, and our vision of a healthier future for patients. For more than 20 years, our scientists have been relentlessly committed to developing differentiated therapies for the GI market. Since the late 1990s, we have been focused on pioneering the research and development of uroguanylin analogs, a naturally occurring human GI peptide, through our clinical work. Our goal is to develop innovative treatments that improve efficacy, safety and tolerability and deliver a better experience for patients living with chronic idiopathic constipation (CIC), irritable bowel syndrome with constipation (IBS-C), opioid-induced constipation (OIC), and ulcerative colitis (UC). We are committed to scientifically driven innovation, providing novel treatment options for patients and healthcare providers, rewarding opportunities for our employees, and creating exceptional value for our customers. You can find us based in New York City, with research, technical operations and commercial offices in suburban Philadelphia. Learn more about our company here: http://www.synergypharma.com/about-us You can also follow us on Twitter: @SynergyPharma Open Innovation, Biotechnology, Gastrointestinal (GI) research and development, Gastrointestinal therapies Open 420 Lexington Avenue, Suite 2012 New York City New York US 10170 Synergy Pharmaceuticals Health Care Pharmaceuticals & Biotechnology
nasdaq:sgyp 2693782 Feb 26th, 2022 12:00AM Synergy Pharmaceuticals Inc. 4.1K 38.00 Open Biotechnology Feb 26th, 2022 04:36PM Feb 26th, 2022 04:36PM At Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), we’re igniting change in gastrointestinal (GI) medicine to develop new treatments with the potential to improve the lives of patients. Our values guide every aspect of our business—our relationships with customers, our approach to science and innovation, and our vision of a healthier future for patients. For more than 20 years, our scientists have been relentlessly committed to developing differentiated therapies for the GI market. Since the late 1990s, we have been focused on pioneering the research and development of uroguanylin analogs, a naturally occurring human GI peptide, through our clinical work. Our goal is to develop innovative treatments that improve efficacy, safety and tolerability and deliver a better experience for patients living with chronic idiopathic constipation (CIC), irritable bowel syndrome with constipation (IBS-C), opioid-induced constipation (OIC), and ulcerative colitis (UC). We are committed to scientifically driven innovation, providing novel treatment options for patients and healthcare providers, rewarding opportunities for our employees, and creating exceptional value for our customers. You can find us based in New York City, with research, technical operations and commercial offices in suburban Philadelphia. Learn more about our company here: http://www.synergypharma.com/about-us You can also follow us on Twitter: @SynergyPharma Open Innovation, Biotechnology, Gastrointestinal (GI) research and development, Gastrointestinal therapies Open 420 Lexington Avenue, Suite 2012 New York City New York US 10170 Synergy Pharmaceuticals Health Care Pharmaceuticals & Biotechnology
nasdaq:sgyp 2693782 Feb 25th, 2022 12:00AM Synergy Pharmaceuticals Inc. 4.1K 38.00 Open Biotechnology Feb 25th, 2022 10:36AM Feb 25th, 2022 10:36AM At Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), we’re igniting change in gastrointestinal (GI) medicine to develop new treatments with the potential to improve the lives of patients. Our values guide every aspect of our business—our relationships with customers, our approach to science and innovation, and our vision of a healthier future for patients. For more than 20 years, our scientists have been relentlessly committed to developing differentiated therapies for the GI market. Since the late 1990s, we have been focused on pioneering the research and development of uroguanylin analogs, a naturally occurring human GI peptide, through our clinical work. Our goal is to develop innovative treatments that improve efficacy, safety and tolerability and deliver a better experience for patients living with chronic idiopathic constipation (CIC), irritable bowel syndrome with constipation (IBS-C), opioid-induced constipation (OIC), and ulcerative colitis (UC). We are committed to scientifically driven innovation, providing novel treatment options for patients and healthcare providers, rewarding opportunities for our employees, and creating exceptional value for our customers. You can find us based in New York City, with research, technical operations and commercial offices in suburban Philadelphia. Learn more about our company here: http://www.synergypharma.com/about-us You can also follow us on Twitter: @SynergyPharma Open Innovation, Biotechnology, Gastrointestinal (GI) research and development, Gastrointestinal therapies Open 420 Lexington Avenue, Suite 2012 New York City New York US 10170 Synergy Pharmaceuticals Health Care Pharmaceuticals & Biotechnology
nasdaq:sgyp 2693782 Feb 24th, 2022 12:00AM Synergy Pharmaceuticals Inc. 4.1K 38.00 Open Biotechnology Feb 24th, 2022 08:47AM Feb 24th, 2022 08:47AM At Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), we’re igniting change in gastrointestinal (GI) medicine to develop new treatments with the potential to improve the lives of patients. Our values guide every aspect of our business—our relationships with customers, our approach to science and innovation, and our vision of a healthier future for patients. For more than 20 years, our scientists have been relentlessly committed to developing differentiated therapies for the GI market. Since the late 1990s, we have been focused on pioneering the research and development of uroguanylin analogs, a naturally occurring human GI peptide, through our clinical work. Our goal is to develop innovative treatments that improve efficacy, safety and tolerability and deliver a better experience for patients living with chronic idiopathic constipation (CIC), irritable bowel syndrome with constipation (IBS-C), opioid-induced constipation (OIC), and ulcerative colitis (UC). We are committed to scientifically driven innovation, providing novel treatment options for patients and healthcare providers, rewarding opportunities for our employees, and creating exceptional value for our customers. You can find us based in New York City, with research, technical operations and commercial offices in suburban Philadelphia. Learn more about our company here: http://www.synergypharma.com/about-us You can also follow us on Twitter: @SynergyPharma Open Innovation, Biotechnology, Gastrointestinal (GI) research and development, Gastrointestinal therapies Open 420 Lexington Avenue, Suite 2012 New York City New York US 10170 Synergy Pharmaceuticals Health Care Pharmaceuticals & Biotechnology
nasdaq:sgyp 2693782 Feb 23rd, 2022 12:00AM Synergy Pharmaceuticals Inc. 4.1K 38.00 Open Biotechnology Feb 23rd, 2022 08:39AM Feb 23rd, 2022 08:39AM At Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), we’re igniting change in gastrointestinal (GI) medicine to develop new treatments with the potential to improve the lives of patients. Our values guide every aspect of our business—our relationships with customers, our approach to science and innovation, and our vision of a healthier future for patients. For more than 20 years, our scientists have been relentlessly committed to developing differentiated therapies for the GI market. Since the late 1990s, we have been focused on pioneering the research and development of uroguanylin analogs, a naturally occurring human GI peptide, through our clinical work. Our goal is to develop innovative treatments that improve efficacy, safety and tolerability and deliver a better experience for patients living with chronic idiopathic constipation (CIC), irritable bowel syndrome with constipation (IBS-C), opioid-induced constipation (OIC), and ulcerative colitis (UC). We are committed to scientifically driven innovation, providing novel treatment options for patients and healthcare providers, rewarding opportunities for our employees, and creating exceptional value for our customers. You can find us based in New York City, with research, technical operations and commercial offices in suburban Philadelphia. Learn more about our company here: http://www.synergypharma.com/about-us You can also follow us on Twitter: @SynergyPharma Open Innovation, Biotechnology, Gastrointestinal (GI) research and development, Gastrointestinal therapies Open 420 Lexington Avenue, Suite 2012 New York City New York US 10170 Synergy Pharmaceuticals Health Care Pharmaceuticals & Biotechnology
nasdaq:sgyp 2693782 Feb 22nd, 2022 12:00AM Synergy Pharmaceuticals Inc. 4.1K 38.00 Open Biotechnology Feb 22nd, 2022 10:29AM Feb 22nd, 2022 10:29AM At Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), we’re igniting change in gastrointestinal (GI) medicine to develop new treatments with the potential to improve the lives of patients. Our values guide every aspect of our business—our relationships with customers, our approach to science and innovation, and our vision of a healthier future for patients. For more than 20 years, our scientists have been relentlessly committed to developing differentiated therapies for the GI market. Since the late 1990s, we have been focused on pioneering the research and development of uroguanylin analogs, a naturally occurring human GI peptide, through our clinical work. Our goal is to develop innovative treatments that improve efficacy, safety and tolerability and deliver a better experience for patients living with chronic idiopathic constipation (CIC), irritable bowel syndrome with constipation (IBS-C), opioid-induced constipation (OIC), and ulcerative colitis (UC). We are committed to scientifically driven innovation, providing novel treatment options for patients and healthcare providers, rewarding opportunities for our employees, and creating exceptional value for our customers. You can find us based in New York City, with research, technical operations and commercial offices in suburban Philadelphia. Learn more about our company here: http://www.synergypharma.com/about-us You can also follow us on Twitter: @SynergyPharma Open Innovation, Biotechnology, Gastrointestinal (GI) research and development, Gastrointestinal therapies Open 420 Lexington Avenue, Suite 2012 New York City New York US 10170 Synergy Pharmaceuticals Health Care Pharmaceuticals & Biotechnology
nasdaq:sgyp 2693782 Feb 21st, 2022 12:00AM Synergy Pharmaceuticals Inc. 4.1K 39.00 Open Biotechnology Feb 21st, 2022 08:53AM Feb 21st, 2022 08:53AM At Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), we’re igniting change in gastrointestinal (GI) medicine to develop new treatments with the potential to improve the lives of patients. Our values guide every aspect of our business—our relationships with customers, our approach to science and innovation, and our vision of a healthier future for patients. For more than 20 years, our scientists have been relentlessly committed to developing differentiated therapies for the GI market. Since the late 1990s, we have been focused on pioneering the research and development of uroguanylin analogs, a naturally occurring human GI peptide, through our clinical work. Our goal is to develop innovative treatments that improve efficacy, safety and tolerability and deliver a better experience for patients living with chronic idiopathic constipation (CIC), irritable bowel syndrome with constipation (IBS-C), opioid-induced constipation (OIC), and ulcerative colitis (UC). We are committed to scientifically driven innovation, providing novel treatment options for patients and healthcare providers, rewarding opportunities for our employees, and creating exceptional value for our customers. You can find us based in New York City, with research, technical operations and commercial offices in suburban Philadelphia. Learn more about our company here: http://www.synergypharma.com/about-us You can also follow us on Twitter: @SynergyPharma Open Innovation, Biotechnology, Gastrointestinal (GI) research and development, Gastrointestinal therapies Open 420 Lexington Avenue, Suite 2012 New York City New York US 10170 Synergy Pharmaceuticals Health Care Pharmaceuticals & Biotechnology
nasdaq:sgyp 2693782 Feb 20th, 2022 12:00AM Synergy Pharmaceuticals Inc. 4.1K 39.00 Open Biotechnology Feb 20th, 2022 03:12PM Feb 20th, 2022 03:12PM At Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), we’re igniting change in gastrointestinal (GI) medicine to develop new treatments with the potential to improve the lives of patients. Our values guide every aspect of our business—our relationships with customers, our approach to science and innovation, and our vision of a healthier future for patients. For more than 20 years, our scientists have been relentlessly committed to developing differentiated therapies for the GI market. Since the late 1990s, we have been focused on pioneering the research and development of uroguanylin analogs, a naturally occurring human GI peptide, through our clinical work. Our goal is to develop innovative treatments that improve efficacy, safety and tolerability and deliver a better experience for patients living with chronic idiopathic constipation (CIC), irritable bowel syndrome with constipation (IBS-C), opioid-induced constipation (OIC), and ulcerative colitis (UC). We are committed to scientifically driven innovation, providing novel treatment options for patients and healthcare providers, rewarding opportunities for our employees, and creating exceptional value for our customers. You can find us based in New York City, with research, technical operations and commercial offices in suburban Philadelphia. Learn more about our company here: http://www.synergypharma.com/about-us You can also follow us on Twitter: @SynergyPharma Open Innovation, Biotechnology, Gastrointestinal (GI) research and development, Gastrointestinal therapies Open 420 Lexington Avenue, Suite 2012 New York City New York US 10170 Synergy Pharmaceuticals Health Care Pharmaceuticals & Biotechnology

Request a demo to view additional historical data, and much more.

Request Demo

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.